Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
39.8M
-
Shares change
-
+9.95M
-
Total reported value, excl. options
-
$218M
-
Value change
-
+$54.9M
-
Number of buys
-
28
-
Number of sells
-
-13
-
Price
-
$5.51
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q1 2017
54 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q1 2017.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.8M shares
of 1.57B outstanding shares and own 2.53% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (12M shares), Capital World Investors (6.79M shares), FMR LLC (6.28M shares), ORBIMED ADVISORS LLC (1.91M shares), Tekla Capital Management LLC (1.47M shares), QVT Financial LP (1.36M shares), Hillhouse Capital Management, Ltd. (1.19M shares), BAILLIE GIFFORD & CO (921K shares), AXA (900K shares), and Rock Springs Capital Management LP (875K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.